Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (KNSA) announced a conference call and live webcast on November 1, 2022, at 8:30 a.m. ET to discuss its third quarter 2022 financial results and corporate activities. Interested participants can access the call via Kiniksa's website or register for telephone participation. A replay will be available approximately 48 hours after the event. Kiniksa focuses on developing therapeutic medicines addressing significant unmet medical needs, with assets including ARCALYST, KPL-404, and mavrilimumab.
Positive
- Kiniksa is expanding its portfolio with promising assets targeting underserved conditions.
- The scheduled call indicates transparency and engagement with investors regarding financial performance.
Negative
- No specific financial results or metrics disclosed prior to the conference call.
Insights
Analyzing...
HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022, at 8:30 a.m. Eastern Time to report its third quarter 2022 financial results and corporate activities.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST®, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
| Every Second Counts! ® Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com |
FAQ
When is Kiniksa's Q3 2022 financial results conference call?
How can I access Kiniksa's conference call?
What assets does Kiniksa Pharmaceuticals focus on?
